EXACT Sciences Corporation (EXAS) : 10 analysts are covering EXACT Sciences Corporation (EXAS) and their average rating on the stock is 2, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
EXACT Sciences Corporation (EXAS) : The highest level EXACT Sciences Corporation (EXAS) is projected to reach is $18 for the short term and the lowest estimate is at $7. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $11.83 and the possibility the share price can swing is $3.81.
EXACT Sciences Corporation (NASDAQ:EXAS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.87 and $11.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $12.43. The buying momentum continued till the end and the stock did not give up its gains. It closed at $12.39, notching a gain of 4.47% for the day. The total traded volume was 2,759,458 . The stock had closed at $11.86 on the previous day.
Also, Craig-Hallum upgrades their rating on the shares of EXACT Sciences Corporation (NASDAQ:EXAS). The current rating of the shares is Buy. Earlier, the shares were rated a Hold by the brokerage firm. Equity Analysts at the Firm raises the price target to $18 per share. The rating by the firm was issued on June 16, 2016. The company shares have dropped -56.48% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $29.40 and the one year low was seen on Mar 1, 2016. The 50-Day Moving Average price is $8.45 and the 200 Day Moving Average price is recorded at $7.20.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.